1. Home
  2. CHMI vs GANX Comparison

CHMI vs GANX Comparison

Compare CHMI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHMI
  • GANX
  • Stock Information
  • Founded
  • CHMI 2012
  • GANX 2017
  • Country
  • CHMI United States
  • GANX United States
  • Employees
  • CHMI N/A
  • GANX N/A
  • Industry
  • CHMI Real Estate Investment Trusts
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHMI Real Estate
  • GANX Health Care
  • Exchange
  • CHMI Nasdaq
  • GANX Nasdaq
  • Market Cap
  • CHMI 83.3M
  • GANX 79.8M
  • IPO Year
  • CHMI 2013
  • GANX 2021
  • Fundamental
  • Price
  • CHMI $2.40
  • GANX $3.16
  • Analyst Decision
  • CHMI Hold
  • GANX Strong Buy
  • Analyst Count
  • CHMI 3
  • GANX 6
  • Target Price
  • CHMI $2.75
  • GANX $8.00
  • AVG Volume (30 Days)
  • CHMI 305.8K
  • GANX 1.2M
  • Earning Date
  • CHMI 11-06-2025
  • GANX 11-12-2025
  • Dividend Yield
  • CHMI 17.78%
  • GANX N/A
  • EPS Growth
  • CHMI N/A
  • GANX N/A
  • EPS
  • CHMI 0.02
  • GANX N/A
  • Revenue
  • CHMI $40,202,000.00
  • GANX N/A
  • Revenue This Year
  • CHMI N/A
  • GANX N/A
  • Revenue Next Year
  • CHMI $52.49
  • GANX N/A
  • P/E Ratio
  • CHMI $120.09
  • GANX N/A
  • Revenue Growth
  • CHMI N/A
  • GANX N/A
  • 52 Week Low
  • CHMI $2.17
  • GANX $1.41
  • 52 Week High
  • CHMI $3.68
  • GANX $3.06
  • Technical
  • Relative Strength Index (RSI)
  • CHMI 55.23
  • GANX 69.79
  • Support Level
  • CHMI $2.20
  • GANX $2.60
  • Resistance Level
  • CHMI $2.42
  • GANX $3.05
  • Average True Range (ATR)
  • CHMI 0.10
  • GANX 0.31
  • MACD
  • CHMI 0.01
  • GANX 0.04
  • Stochastic Oscillator
  • CHMI 75.77
  • GANX 84.81

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: